Format

Send to

Choose Destination
Int J Clin Exp Med. 2015 Jun 15;8(6):9374-83. eCollection 2015.

Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.

Author information

1
Department of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China ; Department of Hematology, The First People's Hospital of Yuhang District Hangzhou 311100, Zhejiang, China.
2
Department of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.

Abstract

OBJECTIVE:

To observe the clinical effects and adverse reactions, and analyze the clinical significance of L-asparaginase (L-ASP) containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma (PTCL).

METHODS:

A retrospective analysis was conducted of 102 patients with incipient PTCL who received L-ASP containing multidrug chemotherapy regimens or not in our hospital from January 2010 to December 2013. Complete remission (CR) rate, partial remission (PR) rate, overall remission (OR) rate, progression free survival (PFS), overall survival (OS) and adverse reactions were compared.

RESULTS:

Patients who received L-ASP containing multidrug chemotherapy (L-ASP group) had higher OR rate than those who received L-ASP-free ones (non L-ASP group) (83.3% vs 61.7%, P=0.016), particularly those at phase III/IV (82.4% vs 54.0%, P=0.007) and with an international prognostic index (IPI) score of ≥2 (82.1% vs 50.0%, P=0.006). The median survival time (OS) was 10.5 months (range, 1-47months) in L-ASP group, while 13 months (range, 0.3-68 months) in non L-ASP group, and they had no statistically significance (P=0.754). Similarly, the progression free survival time(PFS)was 10 months (range, 1-47 months) in L-ASP group,while 11 months (range, 0.3-68 months) in non L-ASP group, also had no statistically significance (P=0.414). The 3-year OS rate of L-ASP group and non L-ASP group were 48.9% and 65.0% , respectively (P=0.974) and the 3-year PFS rate of L-ASP group and non L-ASP group were 40.8% and 61.0%, respectively (P=0.479). They all had no statistically significance. The L-ASP group had more adverse reactions than the non L-ASP group, though most of them were mild and could be improved by symptomatic and supportive care.

CONCLUSION:

L-ASP containing multidrug chemotherapy regimen in incipient PTCL showed a better short-term effect and controllable adverse reactions. A large prospective clinical trial of use L-ASP in first-line treatment of PTCL is worthy of further research and investigation.

KEYWORDS:

Lymphoma; adverse reaction; effect; l-asparaginase; peripheral t-cell; safety

PMID:
26309599
PMCID:
PMC4537992

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center